For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.

Title'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.
Publication TypeJournal Article
Year of Publication2018
AuthorsScott A, Weber N, Tiley C, Taylor K, Taper J, Harrison S, Chan K-L, Stark R, Lee C, Morris K, P Ho J, Dodds A, Ramanathan S, Ramakrishna R, Watson A-M, Auguston B, Kwok F, Quach H, Warburton P, Rowlings P, Mollee P
JournalLeuk Lymphoma
Volume59
Issue6
Pagination1514-1516
Date Published2018 06
ISSN1029-2403
KeywordsAntineoplastic Combined Chemotherapy Protocols, Australia, Drug Resistance, Neoplasm, Humans, Immunologic Factors, Multiple Myeloma, Recurrence, Retreatment, Thalidomide, Treatment Outcome
DOI10.1080/10428194.2017.1387911
Alternate JournalLeuk Lymphoma
PubMed ID29022836